Report: Herbal Supplements, Prescription Drugs, Rx-to-OTC Products: A Comparison TOC

INTRODUCTION
- OBJECTIVES AND GOALS OF THE STUDY
- CONTRIBUTION OF THE STUDY AND FOR WHOM
- SCOPE AND CONTENT
- METHODOLOGY
- INFORMATION SOURCES
- AUTHOR' S CREDENTIALS
- RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
EXECUTIVE SUMMARY
- Summary Table:
- GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
- Summary Figure:
- GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, 2004-2011 ($ MILLIONS)
OVERVIEW
- THE HERBAL SUPPLEMENT, PRESCRIPTION AND OVER-THE-COUNTER DRUG MARKETS
  - DEFINITION OF AN HERBAL SUPPLEMENT
- U.S. REGULATIONS RELATING TO HERBAL SUPPLEMENTS
- U.S. ISSUES FIRST HERBAL SUPPLEMENT STANDARDS
- NONGOVERNMENT OVERSIGHT OF HERBAL PRODUCT QUALITY
- OVERSEAS REGULATIONS RELATING TO HERBAL SUPPLEMENTS
- REIMBURSEMENT FOR HERBAL PRODUCTS IN THE E.U.
  - THE WORLD HEALTH ORGANIZATION RELEASES GUIDELINES FOR MEDICINAL HERBS
- SOURCES OF RAW MATERIALS FOR HERBAL SUPPLEMENTS
  - THE CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES OF WILD FAUNA AND FLORA
  - TERMS USED TO DESCRIBE THE SOURCES OF HERBS USED IN SUPPLEMENTS
- USE OF HERBAL SUPPLEMENTS WORLDWIDE
  - CURRENT BEST-SELLING HERBAL SUPPLEMENTS AND INDICATIONS FOR HERBAL SUPPLEMENTS
- FORECASTING BY PRODUCT
- THE ACTIVE INGREDIENTS IN AND INDICATIONS FOR POPULAR HERBAL SUPPLEMENTS
- Table 1 ACTIVE INGREDIENTS AND INDICATIONS FOR SELECTED POPULAR HERBAL
- SUPPLEMENTS
- Table 1 (CONTINUED)
  - ADVERSE HERB-DRUG INTERACTIONS
  - LEADING HERBAL SUPPLEMENTS WORLDWIDE
    - BILBERRY
    - BLACK COHOSH
    - ECHINACEA
    - ELDERBERRY
    - ELEUTHERO
    - EVENING PRIMROSE
- Table 2 CONCENTRATED SOURCES OF GLA
  - Evening Primrose (Continued)
- GARLIC
  - Garlic (Continued)
- GINGER
- GINKGO
  - Ginkgo (Continued)
  - Ginkgo (Continued)
- GINSENG
  - Ginseng (Continued)
  - Ginseng (Continued)
- Table 3 AVERAGE PRICE PER DRY POUND OF GINSENG, BASED ON THE SOURCE OF THE ROOT ($/LB.)
  - Ginseng (Continued)
- GOLDENSEAL
- GRAPE SEED EXTRACT
- GREEN TEA
  - Green Tea (Continued)
- HORNY GOAT WEED
- KAVA KAVA
- MILK THISTLE
- PYGEUM
- ST. JOHN' S WORT
  - St. John' s Wort (Continued)
- SAW PALMETTO
  - Saw Palmetto (Continued)
- SOY
  - Soy (Continued)
- VALERIAN
- YOHIMBE
  - THE PRESCRIPTION DRUG INDUSTRY
APPLICATIONS AND PRODUCTS
- HERBAL SUPPLEMENT AND PRESCRIPTION DRUG MARKETS TO TREAT SELECTED ISEASES AND CONDITIONS
- Table 4 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS FOR DISEASES, THROUGH 2011 ($ MILLIONS)
- Table 5 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)
- Table 6 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)
- Figure 2 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)
  - THE GLOBAL MARKET FOR HERBAL SUPPLEMENTS
- Table 7 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, THROUGH 2011 ($ MILLIONS)
- Figure 3 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, 2004-2011 ($ MILLIONS)
- Table 8 ESTIMATED GLOBAL MARKET FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)
  - THE U.S. MARKET FOR HERBAL SUPPLEMENTS
    - Top-Selling Herbal Supplements in the U.S.
- Table 9 THE TOP-SELLING HERBAL SUPPLEMENTS IN THE U.S. MARKET IN 2002 THROUGH FOOD, DRUG AND MASS MARKET CHANNELS ($ MILLIONS)
- Table 10 U.S. MARKET FORECAST FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)
- Table 11 PERCENTAGE OF THE U.S. HERBAL SUPPLEMENTS MARKET HELD BY MULTIPLE-HERB FORMULAS, 2003-2005 (%)
  - SALES OF HERBAL SUPPLEMENTS IN THE U.S. BY DISTRIBUTION CHANNEL
- Table 12 U.S. MARKET FORECAST FOR SALES OF HERBAL TREATMENTS, BY DISTRIBUTION CHANNEL, THROUGH 2011 ($ MILLIONS)
- Table 13 THE TOP-SELLING HERBAL SUPPLEMENTS SOLD THROUGH FOOD, DRUG AND MASS MARKET CHANNELS IN THE U.S, 2004 AND 2005 ($ MILLIONS)
  - PRESCRIPTION PHARMACEUTICAL PRODUCTS
    - BEST-SELLING DRUGS IN 2005
  - BENIGN PROSTATIC HYPERPLASIA
    - HERBAL SUPPLEMENTS FOR THE TREATMENT OF BPH
    - THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT BPH
- Table 14 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION DRUGS TO TREAT BPH
    - Prescription Drugs to Treat BPH (Continued)
    - Generic Proscar Introduced
      - The Market for Prescription Drugs to Treat BPH
- Table 15 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)
- Figure 4 MARKET SHARE OF PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, 2005 (%)
- Figure 4 (CONTINUED)
- Table 16 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT BPH
- Table 17 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF BPH
  - BXL 628
  - Cetrorelix
  - Lonidamine
  - QLT-0087
  - Silodosin
  - Tadalafil
- COGNITIVE DISORDERS
  - HERBAL SUPPLEMENTS TO TREAT COGNITIVE DISORDERS
  - THE MARKET FOR HERBAL SUPPLMENTS TO TREAT COGNITIVE DISORDERS
- Table 18 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT COGNITIVE DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION MEDICATIONS TO TREAT COGNITIVE DISORDERS
  - THE MARKET FOR PRESCRIPTION MEDICATIONS TO TREAT COGNITIVE DISORDERS
- Table 19 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 20 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, THROUGH 2011 ($ MILLIONS)
  - DRUGS IN DEVELOPMENT TO TREAT COGNITIVE DISORDERS
- Table 21 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF COGNITIVE DISORDERS
  - Namenda
    - Alzhemed
    - Flurizan
    - Namenda
    - Neramexane
- DEPRESSION
  - DEPRESSION (Continued)
  - DEPRESSION (Continued)
  - HISTORY OF ANTIDEPRESSANT MEDICATIONS
  - HERBAL SUPPLEMENTS TO TREAT DEPRESSION
  - THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT DEPRESSION
- Table 22 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT DEPRESSION, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION DRUGS TO TREAT DEPRESSION
    - Cymbalta
    - Effexor/Effexor Xr
    - Lexapro
    - Remeron
    - Wellbutrin/Wellbutrin SR/Wellbutrin XL
    - Zoloft
    - Generic Versions of Best-selling Antidepressants
    - Revived Interest in Older Antidepressants
    - Antidepressants Recently Withdrawn From the Market
    - FDA Issues Warning on Use of Antidepressants in Children and Adolescents, and Perhaps Adults
  - THE MARKET FOR PRESCRIPTION DRUGS TO TREAT DEPRESSION
- Table 23 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 24 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)
- Figure 5 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)
  - PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT DEPRESSION
- Table 25 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF DEPRESSION
- Table 25 (CONTINUED)
  - DVS-233 SR
- ERECTILE DYSFUNCTION
  - HERBAL SUPPLEMENTS TO TREAT ERECTILE DYSFUNCTION
  - THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT ERECTILE DYSFUNCTION
- Table 26 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT ERECTILE DYSFUNCTION, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION DRUGS TO TREAT ERECTILE DYSFUNCTION
    - Marketed Products
      - Cialis
      - Levitra
      - Viagra
      - Zydena
- THE MARKET FOR PRESCRIPTION DRUGS TO TREAT ERECTILE DYSFUNCTION
- Table 27 GLOBAL MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 28 U.S. MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
  - DRUGS IN DEVELOPMENT TO TREAT ERECTILE DYSFUNCION
- Table 29 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ERECTILE DYSFUNCTION
  - TA-1790
  - Uprima
  - Vasomax
- GASTROINTESTINAL DISORDERS
  - DYSPEPSIA
  - HEARTBURN/GASTROESOPHAGEAL REFLUX DISEASE
  - NAUSEA
  - THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT GASTROINTESTINAL DISORDERS
- Table 30 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT GASTROINTESTINAL DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PHARMACEUTICAL PRODUCTS TO TREAT GASTROINTESTINAL DISORDERS
    - Antinauseants
      - Locally Acting Antienauseants
      - Centrally Acting Antinauseants
      - Antidopaminergics
      - Antidopaminergics (Continued)
      - Anticholinergics
      - Miscellaneous Antinauseants
      - Miscellaneous Antinauseants (Continued)
- Table 31 MARKETED ANTINAUSEANT PRODUCTS
  - Market Size and Growth
- Table 32 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
- Table 33 ESTIMATED U.S. MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
  - H2 Inhibitors
    - The History of H2 Inhibitors
    - Marketed Prescription Products
      - Marketed Prescription Products (Continued)
- Table 34 MARKETED H2 INHIBITORS
  - Market Size and Growth
- Table 35 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Figure 6 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)
- Table 36 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Figure 7 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)
  - Proton Pump Inhibitors
    - AcipHex/Pariet
    - Nexium
    - Prevacid/Takepron
    - Prilosec/Losec
    - Protonix/Pantozol/Protium
    - Zegerid
    - Generic Proton Pump Inhibitors
    - Comparison of Proton Pump Inhibitors
- Table 37 BRANDED PRESCRIPTION PROTON PUMP INHIBITORS AND SUPPLIERS
  - Cost of Proton Pump Inhibitors
  - The Market for Proton Pump Inhibitors
- Table 38 GLOBAL MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 39 U.S. MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 39 (CONTINUED)
  - Loss of Patent Protection by Leading Prescription Proton Pump Inhibitors
- Table 40 PATENT EXPIRATION FOR SELECTED PRESCRIPTION GASTROINTESTINAL DRUGS, 2005-2013
- Table 40 (CONTINUED)
  - Prescription Gastrointestinal Products in Development
- Table 41 SELECTED GASTROINTESTINAL DISORDER TREATMENTS IN PHASE II OR LATER DEVELOPMENT
  - Prescription versus OTC Proton Pump Inhibitors
  - Over-the-Counter Gastrointestinal Products
    - Antacids
    - Antacids (Continued)
  - Systemic Antacids
    - Sodium Bicarbonate
  - Nonsystemic Antacids
    - Calcium Carbonate
    - Aluminum Products
    - Magnesium Products
    - Combination Products
- Table 42 MARKETED OTC ANTACID PRODUCTS
  - Market Size and Growth
- Table 43 U.S. MARKET FORECAST FOR OTC ANTACIDS, THROUGH 2011 ($ MILLIONS)
  - Antinauseants
- Table 44 MARKETED OTC ANTINAUSEANTS
  - Market Size and Growth
- Table 45 U.S. MARKET FORECAST FOR OTC ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
  - H2 Inhibitors
- Table 46 MARKETED OTC H2 INHIBITORS
  - Market Size and Growth
- Table 47 ESTIMATED U.S. MARKET FOR OTC H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
  - Proton Pump Inhibitors
- Table 48 MARKETED OTC PROTON PUMP INHIBITORS
  - Market Size and Growth
- Table 49 U.S. MARKET FORECAST FOR OTC PROTON PUMP INHIBITORS, THROUGH 2011 ($ MILLIONS)
  - HYPERCHOLESTEROLEMIA
    - HYPERCHOLESTEROLEMIA (Continued)
    - HYPERCHOLESTEROLEMIA (Continued)
    - RELATIONSHIP OF CHOLESTEROL TO CARDIOVASCULAR DISEASE
    - HERBAL TREATMENTS FOR HYPERCHOLESTEROLEMIA
      - Beta Sitosterol
    - THE MARKET FOR HERBAL TREATMENTS FOR HYPERCHOLESTEROLEMIA
- Table 50 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
- Table 51 CLASSES OF LIPID-LOWERING DRUGS
- Table 52 LIPID-LOWERING DRUGS USED IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN CORONARY ARTERY DISEASE
  - Bile Acid-binding Resins
  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
  - Marketed Statin Drugs
- Table 53 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
  - Fibric Acids
  - Nicotinic Acid and Derivatives
  - Probucol
  - Leading Products
  - Combination Products
  - Statin Drugs Show Promise in Treating Prostate Cancer
  - The Entry of Generic Versions of Blockbuster Cholesterol Drugs
  - The Medicare (Part D) Drug Benefit and Statin Drugs
- THE MARKET FOR PRESCRIPTION DRUGS TO TREAT HYPERCHOLESTEROLEMIA
- Table 54 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 55 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
- Table 56 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
  - AGI-1067
  - CETi-1
  - ETC-588
  - ETC-642
  - FM-VP4
  - KS 01-019
  - Lipitor/Torcetrapib
  - MK-524B
  - The OTC Market for Statin Drugs
- HYPERTENSION
  - HYPERTENSION (Continued)
  - HERBAL SUPPLEMENTS FOR THE TREATMENT OF HYPERTENSION
  - THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT HYPERTENSION
- Table 57 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT HYPERTENSION, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERTENSION
  - THE MARKET FOR PRESCRIPTION DRUGS TO TREAT HYPERTENSION
- Table 58 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 58 (CONTINUED)
- Table 59 U.S. MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
- Table 60 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
  - Aliskiren
  - Clevelox
  - Imidapril
  - PW2101
  - Tadalafil
- INSOMNIA
- Table 61 FREQUENCY OF INSOMNIA SYMPTOMS IN THE U.S. ADULT POPULATION (%)
  - HERBAL TREATMENTS FOR INSOMNIA
  - THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT INSOMNIA
- Table 62 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT INSOMNIA, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION DRUGS FOR THE TREATMENT OF INSOMNIA
    - Ambien/ Ambien CR/ Stilnox
    - Benzodiazepines
    - Imovane
    - Lunesta
    - Rozerem
    - Sonata
  - THE MARKET FOR PRESCRIPTION DRUGS TO TREAT INSOMNIA
- Table 63 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 64 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT INSOMNIA
- Table 65 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INSOMNIA
  - Ambien ODT
  - APD125
  - Eplivanaserin SR
  - Gaboxadol
  - Indiplon
  - Posidorm
- OVER-THE-COUNTER TREATMENTS FOR INSOMNIA
- Table 66 ESTIMATED U.S. MARKET FOR OTC PRODUCTS TO TREAT INSOMNIA, THROUGH2011 ($ MILLIONS)
  - MENOPAUSE
    - HERBAL TREATMENTS FOR MENOPAUSAL SYMPTOMS
      - Herbal Treatments for ...(Continued)
    - THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT MENOPAUSAL SYMPTOMS
- Table 67 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, BY HERB, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION DRUGS FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS
    - Prescription Drugs for the...(Continued)
  - THE MARKET FOR PRESCRIPTION DRUGS TO TREAT MENOPAUSAL SYMPTOMS
- Table 68 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 69 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, THROUGH 2011 ($ MILLIONS)
  - PRESCRIPTION DRUGS IN DEVELOPMENT FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS
- Table 70 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS
  - Menopause Formula 101
INDUSTRY
- LEADING PLAYERS IN THE NUTRITIONAL SUPPLEMENTS MARKET
- Table 71 LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS
- Table 72 MARKET SHARES OF LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS IN THE U.S., MARCH 2006 (%)
  - THE INTRODUCTION OF THE MEDICARE DRUG BENEFIT PLAN AND WHAT IT MEANS FOR DRUG SALES.
  - GENERIC DRUGS
    - THERAPEUTIC EQUIVALENCE
- Table 73 FDA ORANGE BOOK THERAPEUTIC EQUIVALENCE RATING CODES
  - STATE POSITIVE FORMULARIES
  - BLOCKBUSTER AGENTS EXPERIENCING GENERIC CHALLENGE IN THE PRESCRIPTION PHARMACEUTICAL MARKET
  - BRAND-NAME COMPANIES ENTER ARRANGEMENTS WITH GENERICS FIRMS TO NOT INTRODUCE GENERIC VERSIONS OF BEST-SELLING DRUGS
  - THE INTRODUCTION OF AUTHORIZED GENERICS
    - The Introduction of ...(Continued)
  - FDA BACKLOG IN REVIEWING GENERIC DRUG APPLICATIONS SLOWS THE ENTRY OF GENERIC DRUGS
  - THE RISE AND FALL IN GENERIC DRUG PRICES
  - GROWTH IN SALES OF GENERIC DRUGS
  - THE TRICKY GENERIC DRUG BUSINESS
  - STRATEGIES EMPLOYED BY GENERICS DRUG COMPANIES
    - First on the Market
    - Full ANDA Pipelines
    - Specialization and Niche Marketing
      - Specialization and ...(Continued)
    - Successful Patent Challenges
    - Exclusive Providers
    - Exclusive Supplier Arrangements
    - Breadth of Product Line
    - Value-added Products
    - Proprietary Products
    - Supergenerics
    - Generic Biologicals
    - Mergers
    - Cost-effective Production
    - Cooperation with Branded Product Manufacturers
  - NOVARTIS TAKES THE LEAD AMONG GENERIC MANUFACTURERS
- THE FDA ISSUES NEW GUIDELINES FOR DIRECT-TO-CONSUMER ADVERTISING
  - THE FDA ISSUES NEW ...(Continued)
COMPANY PROFILES
- HERBAL SUPPLEMENT COMPANIES
  - GNC CORPORATION
    - Business Overview
    - Financial Information
    - Products
    - Company Strategy
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - NATROL INC.
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - NATURAL ALTERNATIVES INTERNATIONAL
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - NATURE' S SUNSHINE PRODUCTS
    - Business Overview
    - Products
  - NBTY, INC.
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - NUTRACEUTICALS INTERNATIONAL
    - Business Overview
    - Financial Information
    - Products
    - Corporation Strategy
- PHARMACEUTICAL COMPANIES
  - ABBOTT LABORATORIES
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - ATHEROGENICS, INC.
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - BIOVAIL, INC.
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
      - Corporate Strategy (Continued)
  - FOREST LABORATORIES
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - GLAXOSMITHKLINE PLC
    - Business Overview
    - Financial Information
    - Products
  - ICOS CORPORATION
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - PFIZER CORPORATION
    - Business Overview
    - Financial Information
    - Products
    - Corporate Strategy
  - SANTARUS, INC.
    - Business Overview
    - Products
    - Corporate Strategy
  - SEPRACOR INC.
    - Business Overview
    - Products
    - Corporate Strategy
LIST OF TABLES
- Summary Table:
- GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
- Table 1 ACTIVE INGREDIENTS AND INDICATIONS FOR SELECTED POPULAR HERBAL SUPPLEMENTS
- Table 2 CONCENTRATED SOURCES OF GLA
- Table 3 AVERAGE PRICE PER DRY POUND OF GINSENG, BASED ON THE SOURCE OF THE ROOT ($/LB.)
- Table 4 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS FOR DISEASES, THROUGH 2011 ($ MILLIONS)
- Table 5 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)
- Table 6 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)
- Table 7 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, THROUGH 2011 ($ MILLIONS)
- Table 8 ESTIMATED GLOBAL MARKET FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)
- Table 9 THE TOP-SELLING HERBAL SUPPLEMENTS IN THE U.S. MARKET IN 2002 THROUGH FOOD, DRUG AND MASS MARKET CHANNELS* ($ MILLIONS)
- Table 10 U.S. MARKET FORECAST FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)
- Table 11 PERCENTAGE OF THE U.S. HERBAL SUPPLEMENTS MARKET HELD BY MULTIPLE-HERB FORMULAS, 2003-2005 (%)
- Table 12 U.S. MARKET FORECAST FOR SALES OF HERBAL TREATMENTS, BY DISTRIBUTION CHANNEL, THROUGH 2011 ($ MILLIONS)
- Table 13 THE TOP-SELLING HERBAL SUPPLEMENTS SOLD THROUGH FOOD, DRUG AND MASS MARKET CHANNELS* IN THE U.S, 2004 AND 2005 ($ MILLIONS)
- Table 14 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 15 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)
- Table 16 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)
- Table 17 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF BPH
- Table 18 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT COGNITIVE DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 19 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 20 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, THROUGH 2011 ($ MILLIONS)
- Table 21 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF COGNITIVE DISORDERS
- Table 22 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT DEPRESSION, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 23 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 24 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)
- Table 25 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF DEPRESSION
- Table 26 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT ERECTILE DYSFUNCTION, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 27 GLOBAL MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 28 U.S. MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 29 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ERECTILE DYSFUNCTION
- Table 30 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT GASTROINTESTINAL DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 31 MARKETED ANTINAUSEANT PRODUCTS
- Table 32 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
- Table 33 ESTIMATED U.S. MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
- Table 34 MARKETED H2 INHIBITORS
- Table 35 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 36 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 37 BRANDED PRESCRIPTION PROTON PUMP INHIBITORS AND SUPPLIERS
- Table 38 GLOBAL MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 39 U.S. MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 40 PATENT EXPIRATION FOR SELECTED PRESCRIPTION GASTROINTESTINAL DRUGS, 2005-2013
- Table 41 SELECTED GASTROINTESTINAL DISORDER TREATMENTS IN PHASE II OR LATER DEVELOPMENT
- Table 42 MARKETED OTC ANTACID PRODUCTS
- Table 43 U.S. MARKET FORECAST FOR OTC ANTACIDS, THROUGH 2011 ($ MILLIONS)
- Table 44 MARKETED OTC ANTINAUSEANTS
- Table 45 U.S. MARKET FORECAST FOR OTC ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
- Table 46 MARKETED OTC H2 INHIBITORS
- Table 47 ESTIMATED U.S. MARKET FOR OTC H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 48 MARKETED OTC PROTON PUMP INHIBITORS
- Table 49 U.S. MARKET FORECAST FOR OTC PROTON PUMP INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 50 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 51 CLASSES OF LIPID-LOWERING DRUGS
- Table 52 LIPID-LOWERING DRUGS USED IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN CORONARY ARTERY DISEASE
- Table 53 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
- Table 54 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 55 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)
- Table 56 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
- Table 57 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT HYPERTENSION, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 58 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 59 U.S. MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)
- Table 60 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
- Table 61 FREQUENCY OF INSOMNIA SYMPTOMS IN THE U.S. ADULT POPULATION (%)
- Table 62 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT INSOMNIA, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 63 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 64 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, THROUGH 2011 ($ MILLIONS)
- Table 65 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INSOMNIA
- Table 66 ESTIMATED U.S. MARKET FOR OTC PRODUCTS TO TREAT INSOMNIA, THROUGH 2011 ($ MILLIONS)
- Table 67 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, BY HERB, THROUGH 2011 ($ MILLIONS)
- Table 68 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 69 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, THROUGH 2011 ($ MILLIONS)
- Table 70 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS
- Table 71 LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS
- Table 72 MARKET SHARES OF LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS IN THE U.S., MARCH 2006 (%)
- Table 73 FDA ORANGE BOOK THERAPEUTIC EQUIVALENCE RATING CODES
LIST OF FIGURES
- Summary Figure:
- GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, 2004-2011 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)
- Figure 2 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)
- Figure 3 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, 2004-2011 ($ MILLIONS)
- Figure 4 MARKET SHARE OF PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, 2005 (%)
- Figure 5 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)
- Figure 6 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)
- Figure 7 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)

Herbal Supplements, Prescription Drugs, Rx-to-OTC Products: A Comparison

Table of Contents